Immunicum AB (publ) Plans to Expand its Research and Process Development Facilities in Leiden, the Netherlands
27 January 2021
Immunicum AB (publ) Plans to Expand its Research and Process Development Facilities in Leiden, the Netherlands
Immunicum AB (publ; IMMU.ST) announced today that its in-house research and process development activities will move into a new facility at the Leiden Bio Science Park, the Netherlands. The Company has signed a long-term lease with developer Kadans Science Partner for approximately 1,100 square meters of laboratory and office space in the Plus Ultra Leiden, a new building currently under development. Furthermore, Immunicum has the option to rent an additional 1,100 square meters to further support its future growth. The new location, that is expected to be fully commissioned in 2022, will serve as Immunicum's core research and development hub.